Photo: Carolina Garcia Tavizon, via Unsplash French biopharmaceutical company Ipsen has entered a global collaboration and option agreement with San Diego-based biotech Origami Therapeutics to advance a small-molecule protein degrader program targeting a rare, inherited neurodegenerative disorder. The deal strengthens Ipsen’s early-stage neuroscience pipeline while giving Origami a potential path toward global development and commercialization
Tag Archive for: Protein degradation
Paris-based start-up Enodia Therapeutics has secured €20.7 million in seed funding to advance its early-stage pipeline of targeted protein degradation. Elaia, Pfizer Ventures and Bpifrance led the Seed financing under the InnoBio investment framework, with further contributions from Wallonie Entreprendre, Argobio Studio, MACSF, the Institut Pasteur, InvestSud, Sambrinvest and Mission BioCapital.
MPI for Biochemistry - AusserhoferResearchers at the Max Planck Institute of Biochemistry (MPIB) and MRC Laboratory of Molecular Biology in Cambridge have developed and patented the new UbiREAD technology, which decodes the complex ubiquitin code that marks target proteins for E3 ligase-mediated degradation in cells.